

ASX Announcement

21 August 2023

Antisense Share Purchase Plan Raises \$3.26 Million

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY], a biotechnology company focused on the development of novel therapies for rare diseases, is pleased to announce the completion of its recent Share Purchase Plan (SPP). The SPP raised gross proceeds of approximately \$3.26 million, which will be applied primarily to the company's ongoing R&D programs.

"We are grateful for the emphatic support of our shareholders in this recent financing round," commented Dr Charmaine Gittleson, Chair of the Board at Antisense Therapeutics. "The funds raised in the recent institutional placement, combined with the proceeds of the SPP, leave the company very well positioned to focus on its ongoing international phase IIb study of ATL1102 in Duchenne muscular dystrophy(DMD). This is an exciting time for Antisense and the DMD community, with key data expected from the phase IIb study in CY2024."

The SPP was launched on 28 July 2023, following completion of a placement to sophisticated and institutional investors which raised gross proceeds of \$8.35 million. The SPP was intended to provide existing holders with the opportunity to strengthen their position in the company on the same terms as participants in the institutional placement, without incurring brokerage or other transaction costs.

The Board had previously indicated an expectation of proceeds from the SPP in the range of \$1.5 – 2.0 million. However, given the strength of support from shareholders, and the promising opportunities the Board anticipates in relation to ATL1102, it has resolved to satisfy all applications in full and not to apply any scale-back to the SPP. Consequently, it is expected that 65,240,000 shares issued under the SPP will be listed for quotation on ASX on Wednesday 23 August 2023, pursuant to ASX Listing Rule 7.2, Exception 5, with holding statements dispatched on the same day.

~ ENDS ~

This announcement has been authorised for release by the Board.

About Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company developing and commercializing antisense pharmaceuticals for rare diseases with significant unmet medical need. The company's lead program is ATL1102, an antisense inhibitor of the CD49d receptor, which is currently the subject of an ongoing international Phase IIb trial for non-ambulant subjects with Duchenne Muscular Dystrophy. The drug previously reported highly promising results from an exploratory Phase II trial in non-ambulant subjects with DMD.

For more information, please contact info@antisense.com.au